Bio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
|
|
- Clemence Lawson
- 6 years ago
- Views:
Transcription
1 Global Strategy Global Challenges Executable Solutions Bio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010
2 Table of Contents Corporate Series (Part 2 of 6) BIOPHARMA: China Preface Overview of the China Life Science Industry The PAST: Evolution of Biopharma Foreign Investment into China The FUTURE: Virtual Integrations 4 th & 5 th Generation Strategies The PRESENT: Strengths, Weaknesses, Opportunities, Threats (SWOT) The OPPORTUNITY: Virtually Integrated Pharma Company (VIPCO s) Next Generation Integrated Global / China Operating Models Traditional Operating Models COSTS / PRODUCTION: Big Pharma Production Trends in China REVENUES / SALES: World s 2 nd Largest Economy (PPP); 400 MM in Middle Class Future Operating Models ( ): Value Chain Focus for Virtual Extensions (China) INNOVATION / R&D: Big Pharma Research & Development (R&D) Trends in China CLINICAL TRIALS: Drivers? Benefits? NEXT GENERATION ( ): Who is Migrating to VIPCO Extended Models? China s Economic Future and Implications for Big Pharma State of Economy: Corporate, Household Balance Sheets; Health of Financial Sector Size, Growth Rate, Robustness across China Economy: Investment / Consumption / Trade State of Export Sector and Impact on the Economy Summary of Future Opportunities for Big Pharma in
3 The PAST: Evolution of Biopharma Foreign Investment into China COST REDUCTION REVENUE / MARKET INNOVATION EFFICIENCY 2) REVENUES 3) INNOVATION Sales Engineering Marketing IT F&A Back Office HR Procure R&D Distribution Production Sourcing RESEARCH & DEVELOPMENT RESOURCES 1) COSTS SALES & MARKETING PRODUCTION / SOURCING DRIVING Shareholder Value 3
4 The FUTURE: Virtual Integrations 4 th & 5 th Generation Strategies REVENUES INNOVATION Sales Engineering Marketing IT F&A Back Office HR Pro c R&D CONTRACTS, PARTNERSHIPS Distribution Sourcing SHARED SERVICE CENTERS Production RESEARCH & DEVELOPMENT SALES & MARKETING RESOURCES COSTS PRODUCTION / SOURCING DRIVING Shareholder Value 4
5 The PRESENT: Strengths, Weaknesses, Opportunities, Threats (SWOT) PATENTS PIPELINES COSTS TALENT EMERGING MARKET OPPORTUNITIES INNOVATION / TALENT Pipeline Productivity Collapse. Big Pharma has doubled investment in R&D during past decade. Yet, the return on this investment has plummeted. Today s new drug yield is barely ½ the new drug production of 10 years ago - despite a doubling in number of compounds being placed into early-stage clinical testing. Globally Transformed Labor Dynamic World is Flat. Extremely high priority and focus placed on national development of scientific base and capabilities in China: already 1.6 million science and engineering graduates per year in PRC (China has 10 x size of graduate pool compared to US). R&D heads /integrates East. R&D and Clinical Trials head East. China clinical trial benefits include Costs Savings (30-50%); Time Savings (30%); Large Technical Talent Pools; Gene Pool advantages in clients; broad infrastructure. REVENUES / MARKETS Global Patent Expirations. Tidal wave of patent expiries this decade: USD150 billion between 2005 and Future for Big Pharma companies rooted in products that are currently under research and development, or have even yet to even be discovered. Emerging Markets already Emerged. Fundamental shift in leading global market sizes, from developed to emerging markets e.g., BRIC (Brazil, Russia, India, China). Today, China is world s #5 largest pharmaceutical market and is projected to be the #2 largest in world by 2020 ($120bn); #1 in Massive Middle Class + Aging Population + Disease Divergence + Insurance = Opportunity. Immense revenue opportunities in China rooted in: divergence of disease profiles; fundamental shift in age profile of its population; massive growth in middle class and incomes; expanding healthcare and insurance infrastructure. COSTS / VALUE CHAIN Healthcare Costs. Massive cost balloon for Big-Pharma across entire global value chain, from Production through R&D. Clinical Trial Costs. Costs of Clinical trials in Western countries more than 2X costs in China. Global Labor Costs. Western Wages are 5 to 10 times Greater than Wages in China, from production operators to scientists and engineers. Need for cheaper costs, but also the quality and IPP. 5
6 The OPPORTUNITY: Virtually Integrated Pharma Company (VIPCO s) FIPCO MODEL VIPCO MODEL (CSO, CMO, CRO, PC-CRO, INSTITUTIONS) FIPCO (Fully Integrated Pharma Co.) Sales & Distribution VIPCO (Virtually Integrated Pharma Co.) Sales & Distribution Partnerships CSOs Manufacturing Manufacturing CMOs Clinical & Regulatory Research Technology Clinical Development Preclinical Support R&D CROs Preclinical CROs Academia, Scientific, Institutions Source: G. S. Burrill, Biotech 2008: A 20/20 Vision to 2020, The Burrill Indiana Life Sciences Meeting, October
7 Bio-Pharma ( ): Next Generation Operating Models 7
8 1. COSTS: Where is Big Pharma Producing Today in China? COST INFRASTRUCTURE TALENT SUPPLY CHAIN IPR China Big Pharma Production Source: All Publically Available Information, Company Websites 8
9 2. REVENUES: China Already World s 2 nd Largest Economy (PPP) GDP PPP (2008) Germany (5) 11,8 trillions de $ US (1) 6,4 trillions China (2) de $ 3,6 trillions de $ India (3) 3 trillions de $ Japan (4) EU-27 UK (7) France (6) $14.3 tr $7.8 tr $3.3 tr $4.4 tr $14.9 tr GDP Nominal (2008) EU-27 Germany (3) US (1) $5.1 tr France (6) UK (4) Japan (2) China (5) IND(9) $14.3 tr $4.9 tr $17.1 tr $4.2 tr $1.2 tr Source: IMF; EIU, CIA World Factbook; F Houdard 9
10 2. REVENUES: How large is China s Middle Class? CHINA MIDDLE CLASS: 300 million (2010) 500 million (2015) Urban Population (millions) Middle Class Income Bands for Urban Population Urban Household Income (US$ PPP-Adjusted) Global > US$107,800 Affluent US$ 3, ,800 Upper Middle US$21,501 53,900 Lower Middle US$13,500 21,500 Poor < US$13, F 2015F 2020F 2025F Upper Middle Class Lower Middle Class Sources: Urbanization Rates, Population based on UN, World Urbanization Prospects 2007; MGI Consumer Demand
11 NEXT GENERATION: Value Chain Focus for Virtual Extensions (China) COST & TIME to DEVELOP 1 DRUG in WEST: 16 YEARS USD1.3 billion drugs Up to 1MM drugs Discovery 10 to 50 Pre-Clinical Testing 4-5 Phase I 2-3 Phase II 1-2 Phase III 1 FDA Market 1 Phase IV years Source: A. DiMasi and HG Grabowski: Managerial & Decision Economics 28 (2007); Zinnov LLC 11
12 3. INNOVATION: Big Pharma Migrating R&D Functions to China COSTS DISEASE DIVERSITY RESEARCH DEVELOPMENT CLINICAL TRIALS Pharma Research & Development Operations in China Source: All Publically Available Information, Company Websites 12
13 3. INNOVATION: China Mobilizes all Resources to Develop Talent CHINA SCIENCE and ENGINEERING GRADUATES: 1.6 MILLION per YEAR University Natural Sciences Degrees ( ) USA China Thousands Sources: National Science Board, Science & Engineering Indicators
14 4/5. CLINICAL TRIALS: Drivers for Increasing Future Extensions to China COST (50%) TIME (50%) INFRASTRUCTURE TALENT PATIENTS COSTS China cost of clinical trials approximately 50% Western costs. China actively incentivizing foreign pharma companies to conduct R&D in country by offering a range of financial and other incentives. INFRASTRUCTURE Numerous world-class medical facilities that meet global requirements for clinical testing. TECHNICAL TALENT China graduating roughly 10x science grads than the US. Large pool of highly trained nurses, physicians, technical personnel Strong IT skills and vast pool of IT engineers. TIME Fast speed of patient enrollment; savings up to 30% on enrollment time. US FDA has established an office in China to help in oversight of trials. PATIENT POOL Vast, diverse, unique diseases across China s heterogeneous population. Huge numbers of flexible and untested patients concentrated in all major cities, very quick and efficient patient recruitment. Sources: Exolus Research; PWC, The changing dynamics of pharma outsourcing in Asia (2008) 14
15 5. NEXT GENERATION: Who Programming to VIPCO Extended Model? MIGRATION to ADVANCED OPERATING MODELS in CHINA: CSO, CMO, CRO CSO Extended Cases China s CRO Market Boehringer Ingelheim First Big Pharma to have entrusted a sole distributor for all of its products in China: Sinopharm. Sinopharm is China s largest pharmaceutical distributor by sales and the only China distributor to cover the entire PRC. Boehringer Ingelheim s sales spiked upward by 45% from 2006 to 2007; Sinopharm saw an annual growth rate of 32%. Pfizer CRO Extended Cases GSK Outsources to Wuxi PharmaTech: synthetic chemistry, parallel medicinal chemistry, and bio-analytical services. It also has a 3-year CRO contract with Wuxi PharmaTech to provide services in the areas of: in-vitro Absorption, Distribution, Metabolism and Excretion (ADME) services. Outsources to Shanghai Institute of Materia Medica (SIMM) chemistry requirements. AstraZeneca Invested USD14 million in Wuxi Pharma Tech for the synthesis of 150,000 compounds. Sources: Goldman Sachs: Healthcare Services: CROs, December 2007; Exolus Research 15
16 Business Consulting Life Sciences For Full Report and More Information Please Contact Us: URL:
17 Disclaimer The opinions represented herein were prepared for information purposes only, at the time of publication. The information represented herein is believed to be reliable, at the time of publication, and was obtained by various public sources also believed to be reliable. The opinions were considered to be accurate at the point of creation, and further, any views, forecasts, or estimates contained herein may be subject to change at anytime without notice. The opinions expressed or implied herein may not be the opinions of the author, also Exolus, or any associated affiliates. This report and the information contained herein collectively, is not offered as, and should not be regarded as, used or relied upon as advice on any matter. It shall not constitute or be construed as a recommendation or solicitation on behalf of the author, and no legal commitment or obligation shall arise by reason of this document. Thus, the reader shall make an independent assessment of opinion s stated herein that shall not be considered a substitute for obtaining advise from the readers advisors. The author shall not accept responsibility, express or implied, with regards to the accuracy and completeness of the information herein, and the author shall be liable whatsoever and howsoever arising in connection to this publication. The author shall not accept, and hereby disclaim, all responsibility and liability to all persons, entities, or organizations for all consequences arising out of any use or reliance on the whole or any part of this publication. This publication should not be reproduced or distributed without the author s consent and is not intended for distribution in any jurisdiction in which this would be prohibited. 17
18
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationThe changing dynamics of pharma outsourcing in Asia:
Industries Pharmaceutical The changing dynamics of pharma outsourcing in Asia: Are you readjusting your sights? Are you readjusting your sights? 1 Table of Contents Ⅰ. Introduction 3 Ⅱ. Strategic context
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationCTS East Coast. Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization. Connect with us to connect with Asia
Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization Connect with us to connect with Asia CTS East Coast Oct 19 th, 2011 Philadelphia Introduction Zuellig Pharma Asia Pacific
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationValmet unique offering with process technology, automation and services. Investor Lunch March 17, 2016 Kari Saarinen, CFO
Valmet unique offering with process technology, automation and services Investor Lunch Kari Saarinen, CFO Agenda Investor lunch 1 2 Valmet s in brief Investment highlights 3 Area development 4 Conclusions
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationIndian CRAMS players to cram in growth: CARE Ratings
January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More information2016 Global Manufacturing Competitiveness Index Report highlights
2016 Global Manufacturing Competitiveness Index Report highlights Years of successful collaboration exploring manufacturing competitiveness In collaboration with leading organizations, Deloitte has explored
More informationUBS Global Life Sciences Conference
September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions
More informationStrengthening the experience and embracing the shift
Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationGlobal D-Biotin Sales Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global D-Biotin Sales Market Report 2016 Global D-Biotin Sales Market Report 2016 Publication ID: QYR091612732 Publication
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationBRIC Surgical Sutures Market Outlook to 2020
BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationSBF Position Paper Megatrends shaping Singapore s Future Economic Strategies and Businesses Ng Siew Quan PwC Singapore
www.pwc.com/sg SBF Position Paper Ng Siew Quan Megatrends shaping Singapore s Future Economic Strategies and Businesses Singapore What is a Megatrend? 1. Megatrends are macroeconomic forces that are shaping
More informationIng-Marie Andersson Drugge Boliden Smelters Director Technology & Strategy 9 March 2015, Dublin. Closing the circle from mining to recycling
Closing the circle from mining to recycling Ing-Marie Andersson Drugge Boliden Smelters Director Technology & Strategy 9 March 2015, Dublin 1 2 Population and income distribution Cumulative share of world
More informationPharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai
Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even
More informationLife Sciences Practice
Life Sciences Practice The healthcare landscape has recently experienced considerable changes, including highly visible public demands for safer and improved healthcare systems. At the core of this is
More informationQuintiles Transnational Corporation Big is Beautiful
Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationOPEC World Oil Outlook edition
Organization of the Petroleum Exporting Countries OPEC World Oil Outlook 2040 2017 edition Presented at presented at Riyadh, 15 November 2017 WOO2017 1 Disclaimer The data, analysis and any other information
More informationICT investment trends in South Africa
ICT investment trends in South Africa Enterprise ICT spending patterns through to the end of 2016 September 2015 KG0177CI Single User Price: US$2995 Introduction Summary Kable s survey of South African
More information2016 Global Manufacturing Competitiveness Initiative Report Highlights
2016 Global Manufacturing Competitiveness Initiative Report Highlights Tim Hanley Global Leader, Consumer and Industrial Products Deloitte LLP MD81 1 Deloitte and US Council on Competitiveness I 2016 Global
More informationFuture Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder
More informationBUSINESS PLAN. AQUATICAM Sustainable Shrimp Aquatic Culture Project POWERED BY: Ref: RADIUS Market Cambodia All Right Reserved
AQUATICAM Sustainable Shrimp Aquatic Culture Project BUSINESS PLAN POWERED BY: Ref: 15032010 2011 RADIUS Market Cambodia All Right Reserved This document set out the key strategic directions for AQUATICAM,
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationMapping the Patient Journey: Harnessing the power of big data and analytics A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A S G ES data and analytics A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced
More informationA drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More information8. Fostering Indian Clinical Trials Industry. 8.1 Clinical Trials Opportunity. Strategy for Increasing Exports of Pharmaceutical Products
8. Fostering Indian Clinical Trials Industry 8.1 Clinical Trials Opportunity India has significant valid population to participate in clinical trials and the country also has proven capabilities in medical
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationBP Energy Outlook 2016 edition
BP Energy Outlook 216 edition Spencer Dale, group chief economist Outlook to 235 bp.com/energyoutlook #BPstats Disclaimer This presentation contains forward-looking statements, particularly those regarding
More informationHelping Pharmas Manage Compliance Risks for Speaker Programs
COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively
More informationMergers and Acquisitions in the Biotechnology Industry
Mergers and Acquisitions in the Biotechnology Industry For venture-backed biotech companies, the approval of a new drug is a long-term prospect that requires extensive time and effort for research, development,
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationTrends and Transformations Facing Pharma in 2017
TH E Y E A R A H E A D : Trends and Transformations Facing Pharma in 2017 Table of Contents 2 Introduction Trend 1: The Rise of Generics Trend 2: Rx Volumes Spike Trend 3: Rise of Cold-Chain Logistics
More informationA world in transition: PwC s 2017 APEC CEO Survey, November APEC CEO Survey. Indonesia findings.
A world in transition: PwC s 2017 APEC CEO Survey, November 2017 2017 APEC CEO Survey Indonesia findings www.pwc.com/apec Key themes Making of the workforce of the future An operating model for a fluid
More informationShared Services in the Financial Services Industry: An Operating Model to Reach Strategic Goals
Shared Services in the Financial Services Industry: An Operating Model to Reach Strategic Goals Financial institutions have sought to enhance back- and middle office operations to deliver sustainable cost
More informationAn analysis of the Swedish Biotech Pipeline April, The Swedish Biotechnology Industry Organization
An analysis of the Swedish Biotech Pipeline April, 2007 The Swedish Biotechnology Industry Organization 0 A Survey of the Swedish Biotech pipeline In February-March 2007 a survey of the Swedish biotech
More informationGlobal Human Embryonic Stem Cell (hesc) Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Human Embryonic Stem Cell (hesc) Market Professional Survey Report 2016 Global Human Embryonic Stem Cell
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationDIGITAL EDITION BONUS CONTENT
DIGITAL EDITION BONUS CONTENT Denise Myshko Forecasting Pharma s Future Given the volatility of today s financial landscape, c ompanies, more than ever, need a robust forecasting strategy that is clear,
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationPharmaceutical and Biotechnology Construction Sector Report - UK Analysis
Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis Published: 16/09/2016 / Number of Pages: 98 / Price: 795.00 Introduction and Overview The 3rd edition of the report'pharmaceutical
More informationA look at the five megatrends that will impact our future. What s driving the future?
A look at the five megatrends that will impact our future. What s driving the future? Five global megatrends We asked each member of the PwC Network Leadership team to select a megatrend that they believe
More informationMARKETS & CUSTOMERS. Progressing globalization. Evolving markets
Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationBIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3
BIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3 Bio Outsourcing Asia TABLE OF CONTENTS September 2008 Vol. 1 Issue 3 CanBiotech Inc. CHINA
More informationInterQual View Quick Reference. Change Healthcare Operations LLC Product Support
InterQual View 2017 Quick Reference Change Healthcare Operations LLC www.changehealthcare.com Product Support 800.274.8374 General Terms: Change Healthcare Operations, LLC and/or one of its subsidiaries
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationClick to edit Master subtitle style. Address to HBS India Business Conference April 4, 2004
Click to edit Master subtitle style Address to HBS India Business Conference April 4, 2004 KEY MESSAGES India can grow at 10 per cent over the next 10 years. A 10 per cent GDP growth is not only possible
More informationRPO Market Summary... Page 2 NEAT Evaluation for RPO... Page 5 Vendor Analysis Summary for ADP.. Page 9
NEAT EVALUATION FOR ADP: RPO RPO Market Summary... Page 2 NEAT Evaluation for RPO.... Page 5 Vendor Analysis Summary for ADP.. Page 9 NelsonHall 2016 1 July 2016 RPO Market Summary Overview A healthy market
More informationSponsors, CROs and all
Sponsors, CROs and all the Rest Disclaimer The views and opinions expressed in the following PowerPoint presentation represent the opinions of the author / speaker and should not be construed as the position
More informationCTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
More informationGlobal Invisible Braces Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Invisible Braces Market Research Report 2016 Global Invisible Braces Market Research Report 2016 Publication
More informationGlobal Endoscopy System Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Endoscopy System Market Research Report 2016 Global Endoscopy System Market Research Report 2016 Publication
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationInterim report January September 2017
Interim report January September 2017 Conference call, November 13 th, 2017 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 425 08, US: +1 646 502 51 18 Peter Wolpert, CEO & Founder Anna Ljung, CFO Disclaimer
More informationExport Breached RM80 billion, Highest on Record
5 May ECONOMIC REVIEW March External Trade Export Breached RM80 billion, Highest on Record Exports continued to expand by double-digit growth in March. For the first time, exports value reached the highest
More informationIS BIOSIMILARS COMPETITIVE INTELLIGENCE DIFFERENT?
IS BIOSIMILARS COMPETITIVE INTELLIGENCE DIFFERENT? Duncan Emerton Senior Director, Syndicated Insights & Analysis FirstView (a division of FirstWord Pharma) T: +44 7964 920415 E: duncan.emerton@firstwordgroup.com
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationPAUL CLAYDON. Partner and European Head of Pharmaceuticals and Biotechnology Group. May 2001
PAUL CLAYDON Partner and European Head of Pharmaceuticals and Biotechnology Group May 2001 1 M&A: INDUSTRY TRENDS IN THE LIFE SCIENCES European Biotech Sector European companies using modern biological
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,
More informationGlobal Talent Mobility: The 21 st Century Business Imperative
Global Talent Mobility: The 21 st Century Business Imperative Friday September 5 th, 2008 Session Objectives Global Talent Mobility: The 21 st Century Business Imperative > Understand the new demands and
More information6. Vision 3: Leading the Japanese economy forward as a high value-added industry"
6. Vision 3: Leading the Japanese economy forward as a high value-added industry" Strategic points for realizing the vision Streamlining and rationalization R&D to create innovative drugs Proactively introducing
More informationIntralinks Studyspace : Electronic Investigator-Controlled Site File (eisf)
Intralinks Studyspace : Electronic Investigator-Controlled Site File (eisf) Introduction Intralinks Studyspace: Electronic Investigator-Controlled Site File (eisf) Intralinks Studyspace eisf solution is
More informationFuture Roadmap for Industry of Surgical Instruments of Pakistan Basit Rauf Director TDAP Sialkot
Future Roadmap for Industry of Surgical Instruments of Pakistan Basit Rauf Director TDAP Sialkot Table of Contents 1. Profile of Industry 2. Product HS Code 3. World Exports of Surgical Instruments 4.
More informationGlobal Transglutaminase Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Transglutaminase Market Research Report 2016 Global Transglutaminase Market Research Report 2016 Publication
More informationFuture Matters US Disclosure
Disclaimer This presentation has been prepared by Samsung Electronics Co., Ltd. (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection
More informationInterQual View Quick Reference. Change Healthcare LLC Product Support
InterQual View 2018 Quick Reference Change Healthcare LLC www.changehealthcare.com Product Support 800.274.8374 PROPRIETARY NOTICE General Terms: Change Healthcare LLC and/or one of its subsidiaries (
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationECPI GLOBAL RENEWABLE ENERGY EQUITY INDEX
ECPI FACTSHEET ECPI GLOBAL EQUITY INDEX The index selects the 40 highest ESG-rated Companies active in the production or trading of energy from sources which are inexhaustible REV. NOVEMBER 14 INFORMATION
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationGlobal Hazelnut Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Hazelnut Market Research Report 2016 Global Hazelnut Market Research Report 2016 Publication ID: QYR101614729
More informationPREVIEW. Benchmarking European Investigator Payments Industry Standard Research
PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation
More informationAmgen Supply Chain Segmentation The Journey to October 23, 2014
Amgen Supply Chain Segmentation The Journey to 2022 October 23, 2014 Introduction Rayne Waller VP Global Supply Chain at Amgen Responsible for: Corporate and Regional Supply Chain Functions Contract Manufacturing
More informationSAP SuccessFactors Compensation
SAP SuccessFactors Compensation With global competition for talent increasing, and with today s business environment changing rapidly, an organization s ability to attract and retain talent has become
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationTryg: Increasing Sales and Customer Satisfaction with SAP SuccessFactors Solutions
Tryg: Increasing Sales and Customer Satisfaction with SAP SuccessFactors Solutions Great products drive sales, right? Not so fast. Tryg, a Danish insurer, realized that the quality of the customer experience
More informationCardinal Health overview and strategic priorities
Cardinal Health overview and strategic priorities Steve Inacker President, Channel Management Medical Segment Copyright 2011, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Cardinal
More informationManagement in Pharmaceutical Industry
Master Program Management: Industrial Management Module: Chemistry for Drug Substances Management in Pharmaceutical Industry Prof. Tatsiana Savitskaya Assoc. Prof. Iryna Kimlenka Lectures 5,6 The Key Aspects:
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationHired Agent Agreement
Hired Agent Agreement AGREEMENT BETWEEN Flenard Enterprises, LLC ("Company") dba Milwaukee Blast, located at 6650 W. State St. Unit D Milwaukee, WI 53213 and Ryan Mueller of Diamond Midwest Invitational
More informationThe room was more than 3/4 full with greater than 150 people in attendance.
Summary The room was more than 3/4 full with greater than 150 people in attendance. The questions were well distributed across all four panelists. All the Panelists were very interactive and were able
More information